Edwards C, Cann P A, Read N W, Holdsworth C D
Gut. 1986 May;27(5):581-6. doi: 10.1136/gut.27.5.581.
The effect of oral lidamidine hydrochloride and subcutaneous long acting somatostatin analogue, SMS 201-995, on stool output and salt and water transport in the small intestine was investigated in a patient with gross secretory diarrhoea caused by a vasoactive intestinal polypeptide (VIP) secreting tumour in the liver. Transport in the jejunum and ileum were assessed by steady state perfusion techniques. Under basal conditions, the patient was absorbing fluid and electrolytes from the jejunum and ileum, but at rates that were abnormally low. Lidamidine had no effect on either intestinal transport or stool frequency and output. SMS 201-995 increased intestinal absorption in the jejunum and ileum, reduced plasma VIP concentrations, daily stool frequency and weight, and enabled the patient to resume a normal diet without oral or intravenous fluid and electrolyte supplements. After two months of treatment, medical control was becoming increasingly difficult and stool output had risen again to 2 litres per day. Surgical resection, fortunately, was possible and led to resolution of symptoms and normal plasma VIP concentrations.
在一名因肝脏中分泌血管活性肠肽(VIP)的肿瘤导致严重分泌性腹泻的患者中,研究了口服盐酸利达脒和皮下注射长效生长抑素类似物SMS 201-995对小肠粪便排出量以及盐和水转运的影响。通过稳态灌注技术评估空肠和回肠的转运情况。在基础条件下,患者从空肠和回肠吸收液体和电解质,但速率异常低。利达脒对肠道转运或粪便频率及排出量均无影响。SMS 201-995增加了空肠和回肠的肠道吸收,降低了血浆VIP浓度、每日粪便频率和重量,并使患者能够在无需口服或静脉补充液体和电解质的情况下恢复正常饮食。治疗两个月后,病情控制变得越来越困难,粪便排出量再次升至每天2升。幸运的是,手术切除是可行的,症状得以缓解,血浆VIP浓度恢复正常。